EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial

Cheng Zhou, Yan Zhao, Guannan Zhu, Liming Wu, Yi Liu, Xiaohua Tao, Hengguang Zhao, Zhu Wei iD, Wei Lu, Weiquan Li, Yangfeng Ding, Xiaohong Zhu und 16 weitere

British Journal of Dermatology · 2026

DOI: 10.1093/bjd/ljag052 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Cheng Zhou und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Keymed Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Moderate-to-severe atopic dermatitis (AD) imposes a significant burden on adolescents and their families, leading to a substantial reduction in quality of life. Treatment options remain limited. Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD.

Objectives

To evaluate the efficacy and safety of stapokibart in adolescents with moderate-to-severe AD.

Methods

In this randomized double-blind placebo-controlled phase III trial (NCT06277765), eligible patients were randomized (2 : 1) to stapokibart 300 mg (loading dose 600 mg) or placebo for 18 weeks. Patients with a baseline weight ≥ 60 kg received subcutaneous stapokibart or placebo every 2 weeks (Q2W), while those weighing 30 to < 60 kg received treatment every 3 weeks (Q3W). All patients were given moisturizers during the entire study period. Co-primary endpoints were the proportions of patients achieving a ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) and an Investigator’s Global Assessment (IGA) score of clear or almost clear (IGA 0 or 1) with ≥ 2-point reduction from baseline (IGA response) at week 18. Safety was also assessed.

Results

Of the 180 enrolled patients, 120 received stapokibart (Q2W, n = 54; Q3W, n = 66) and 60 received placebo (Q2W, n = 26; Q3W, n = 34). In total, 178 (98.9%) patients completed the double-blind treatment. At week 18, higher proportions of patients treated with stapokibart than those treated with placebo achieved EASI 75 [73.9% (n = 88/119) vs. 43% (n = 26/60); difference: 30.5% (95% confidence interval 15.3–44.3; P < 0.001)] and an IGA response [57.1% (n = 68/119) vs. 25% (n = 15/60); difference: 31.8% (95% confidence interval 16.6–44.4; P < 0.001)]. The proportion of patients achieving ≥ 4-point reductions in weekly average of daily Peak Pruritus Numerical Rating Scale score was also significantly higher in the stapokibart group than in the placebo group [36.1% (n = 43/119) vs. 15% (n = 9/60); difference: 21.1% (95% confidence interval 7.4–32.4; P = 0.004)]. The incidence of adverse events was similar between the stapokibart (62.5%; n = 75/120) and placebo (62%; n = 37/60) groups. No conjunctivitis was seen.

Conclusions

Stapokibart has a high efficacy and favourable safety in adolescents with moderate-to-severe AD. An author video to accompany this article is available online.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansAdolescentDouble-Blind MethodFemaleMaleTreatment OutcomeSeverity of Illness IndexChildInjections, SubcutaneousDrug Administration Schedule

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, China.

ORCID-Profile: Zhu Wei, Hao Cheng, Xiao-Yong Man, Jianzhong Zhang

Förderung

  • Keymed Biosciences

Zitieren

APA

Zhou, C., Zhao, Y., Zhu, G., Wu, L., Liu, Y., Tao, X., Zhao, H., Wei, Z., Lu, W., Li, W., Ding, Y., Zhu, X., Hu, G., Cheng, H., Xiao, R., Man, X. Y., Wang, Q., Li, S., Zeng, T., …, & Zhang, J. (2026). Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag052

Vancouver

Zhou C, Zhao Y, Zhu G, Wu L, Liu Y, Tao X, et al. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag052

BibTeX
@article{Zhou2026,
  author = {Zhou, Cheng and Zhao, Yan and Zhu, Guannan and Wu, Liming and Liu, Yi and Tao, Xiaohua and Zhao, Hengguang and Wei, Zhu and Lu, Wei and Li, Weiquan and Ding, Yangfeng and Zhu, Xiaohong and Hu, Guohong and Cheng, Hao and Xiao, Rong and Man, Xiao-Yong and Wang, Qi and Li, Shanshan and Zeng, Tongxiang and Wang, Lihua and Xu, Yufeng and Zhang, Libo and Liu, Wei and Zhao, Guoqing and Jia, Yingmin and Huang, Yanqiu and Chen, Bo and Zhang, Jianzhong},
  title = {Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag052}
}
Kostenlos starten →